Revolutionary Oncolytic Virus Therapy Offers New Hope to Non-Small Cell Lung Cancer Patients: First Patient Dosed in Phase I Trial of TG6050

Transgene (Euronext Paris: TNG), a pioneering biotech firm leading the way in cancer treatments, has announced that their first patient has been dosed in the Delivir clinical trial. This Phase I trial is testing the efficacy of their multi-mechanism oncolytic immunotherapy, TG6050, in patients with recurrent metastatic advanced non-small cell lung cancer (NSCLC). This exciting new development could lead to better treatments and outcomes for those suffering from this deadly form of cancer.

TG6050 is a revolutionary new treatment for cancer that seeks to overcome tumor resistance through a multi-pronged approach. It works by triggering an antitumor response through oncolysis, stimulating the immune system with high concentrations of IL-12 and anti-CTLA4 antibody, and ultimately providing a weapon against the disease.

Delivir, an exciting clinical trial for advanced Non-Small Cell Lung Cancer (NSCLC) patients, is now enrolling up to 36 participants. These individuals have already exhausted traditional therapeutic options, including immunotherapy, and are now seeking new hope with Delivir’s intravenous route. With the trial’s completion expected by late 2024, this could be an important step towards a breakthrough in the treatment of advanced NSCLC.

Transgene’s patented Invir.IO® platform has already demonstrated its potential for IV administration with the data presented for TG6002. Now, TG6050 is set to take it a step further by combining the safety of the platform with the powerful therapeutic potential of two highly immunogenic payloads – IL-12 and a full length anti-CTLA-4 antibody – while reducing any associated systemic toxicity.

Transgene is delighted to commence the first-in-human trial of TG6050, an intravenous treatment for recurrent/metastatic advanced non-small cell lung cancer. TG6050 is a promising oncolytic virus that has multiple mechanisms of action including oncolysis and the induction of an immune response with high intra-tumoral concentrations of IL-12 and anti-CTLA4 antibody.

The intravenous administration of TG6050 allows it to target internal cancer lesions and metastases inaccessible by intratumoral injection, making it a truly remarkable treatment option that has several competitive advantages. We are looking forward to progressing this trial and delivering clinical results for this innovative oncolytic virus.

TG6050 has been proven to be both effective and safe in preclinical and toxicology studies carried out on non-human animal models. The exciting results of these studies were presented at the prestigious AACR Annual Meeting in April 2023 and can be accessed by all. With its promising potential, TG6050 could be a major breakthrough in cancer treatment.

About the Delivir trial (NCT: NCT05788926)

The Delivir trial is a pioneering Phase I study exploring the potential of TG6050 as a single-agent treatment for advanced or metastatic non-small cell lung cancer (NSCLC). Up to 36 patients who have failed to respond to standard therapies such as immunotherapies will participate in the trial, receiving single or repeated doses of TG6050 administered intravenously. This groundbreaking trial aims to identify the most effective dose and dosing schedule for this new treatment.

About TG6050

TG6050 is an oncolytic virus developed with Transgene’s Invir.IO® platform for intravenous administration. It utilizes the patented large capacity Vaccinia virus Copenhagen strain, genetically modified with the double deletion TK-RR- (VVCOPTK-RR-). TG6050 has been engineered to encode human IL-12, a powerful cytokine that triggers an antitumor immune response, and a full length anti-CTLA4 antibody.

This allows for high concentrations of both therapeutic proteins to be delivered locally and selectively in the tumor microenvironment, resulting in a stronger and more effective antitumor response.

By reducing systemic exposure to a very low level, it also increases the safety and tolerability profile of IL-12 and the anti-CTLA4 antibody. TG6050 is being evaluated in the Delivir trial, a Phase I trial conducted in advanced NSCLC patients. To learn more, watch the video detailing TG6050’s mechanism of action here.

About Transgene

Transgene is an innovative biotechnology company striving to revolutionize cancer treatment with targeted immunotherapies. By utilizing powerful viral vector technology, Transgene aims to directly or indirectly target and destroy cancer cells, providing a much-needed breakthrough in the battle against cancer. With their sights set on the future of medicine, Transgene (Euronext: TNG) is leading the charge in the fight against this deadly disease.

The Company has an impressive pipeline of cutting-edge therapeutic vaccines and oncolytic viruses in its clinical-stage programs, providing a wealth of opportunities for breakthrough treatments.

Tessa Therapeutics is revolutionizing cancer treatment with their myvac® platform, offering individualized therapeutic vaccines such as TG4050, as well as TG4001 for the treatment of HPV-positive cancers.

Additionally, their Invir.IO® viral backbone is being used to create three oncolytic viruses: TG6002, BT-001, and TG6050. With these innovative treatments, Tessa Therapeutics is leading the charge in cancer therapy.

Transgene’s myvac® platform is a revolutionary immunotherapy that ushers in the era of precision medicine with a personalized approach. By leveraging Artificial Intelligence capabilities provided by its partner NEC, myvac® is able to identify and select patient-specific mutations to encode into a virus-based immunotherapy, allowing for a fully tailored treatment experience to each individual.

Transgene is revolutionizing oncolytic virus therapies with its cutting-edge Invir.IO® platform. Combining its advanced viral vector engineering expertise, the platform is paving the way for a new generation of powerful multifunctional oncolytic viruses to fight cancer.

Leave a Comment